United States Patent 11,083,730: Scope, Claim Structure, and US Landscape
US Patent 11,083,730 is directed to a drug product concept: a combination analgesic pharmaceutical composition that pairs an amide local anesthetic (specifically bupivacaine or ropivacaine) with meloxicam, delivered via a sustained-release delivery system (including polyorthoester-based formulations and other extended-release platforms). The core scope is defined by (i) the drug pair and exclusion of other actives, (ii) a high anesthetic-to-meloxicam ratio window, and (iii) a large set of claim fallbacks on delivery system chemistries, excipients, compositions, and release performance.
What does the independent claim actually cover (Claim 1)?
Claim 1 is the keystone. It claims a pharmaceutical composition comprising:
- a delivery system
- an amide local anesthetic (generic scope in Claim 1; bupivacaine and ropivacaine are explicit in dependent claims)
- meloxicam
- the amide local anesthetic : meloxicam ratio is about 10:1 to 50:1
- the composition contains no additional active agents
Claim 1 capture implications
- The invention is not merely “bupivacaine + meloxicam.” It is a two-active-only formulation with a specific ratio band.
- The delivery system is broadly defined at the independent level, then narrowed in dependent claims to specific sustained-release architectures.
Key dependent claim hooks
- Drug identity: bupivacaine (Claim 2) or ropivacaine (Claim 3) ([bupivacaine/ropivacaine dependent claims in the claim text you provided]).
- Quantitative drug loading: bupivacaine/ropivacaine 0.1 to 8.0 wt% and meloxicam 0.005% to 1% (Claim 4).
- Sustained release: sustained-release delivery system (Claim 5).
- Formulation medium: aqueous-based delivery system (Claim 6).
- Specific platform embodiments:
- polymeric formulations, liposomes, microspheres, implantable devices, non-polymeric formulations (Claim 7)
- liposome types and entrapment modes (Claims 8-9)
- biodegradable microspheres with entrapment (Claims 10-11)
- osmotic pump reservoirs (Claim 12)
- non-polymeric sustained-release using sucrose acetate isobutyrate (Claim 13)
- semi-solid polymer formulations that form depot/implant in situ (Claims 14-16)
- Polyorthoester structural specificity: multiple claims define polyorthoesters by formula parameters (Claims 17-20, 29-35, 36).
Practical read
- Claim 1 is broad on delivery system, while dependent claims create multiple variant “lanes” that can be enforced even if a competitor avoids one architecture (e.g., avoids liposomes but not polyorthoesters).
How broad is the delivery system scope (Claims 5–20, 21–39)?
Delivery system: sustained-release umbrella
- Claim 5: delivery system is sustained-release.
- Claim 6: delivery system is aqueous based.
These narrow the independent concept toward formulations meant to extend exposure, and away from purely immediate-release systems.
Delivery system: platform-specific carve-outs
- Claim 7: sustained-release delivery system can be:
- polymeric formulation
- liposome
- microsphere
- implantable device
- non-polymeric formulation
This is not a single modality. It is an intentionally wide patent perimeter.
Liposome embodiment
- Claim 8: liposome is selected from:
- Claim 9: entrapment is either:
- in aqueous space
- in lipid layer
This gives multiple formulation structures that can still satisfy the claim.
Microsphere embodiment
- Claims 10-11:
- microsphere comprised of bioerodible or biodegradable polymer
- entrapment of both actives in the microsphere
Implantable device embodiment
- Claim 12: osmotic pump with reservoir containing both actives.
Non-polymeric sustained release
- Claim 13: non-polymeric sustained-release formulation containing sucrose acetate isobutyrate.
Polymeric/semi-solid depot embodiment
- Claims 14-16:
- semi-solid polymer formulation
- polymer is bioerodible or biodegradable
- polymer forms implant or depot in situ
Polymer family scope
- Claim 17: polymer selected from:
- polylactides
- polyglycolides
- PLA/GLY copolymers
- polycaprolactones
- poly-3-hydroxybutyrates
- polyorthoesters
- Claim 18: polyorthoester (explicit).
This creates a “ladder”: generic biodegradable polymers up the stack, then polyorthoesters as a major specific branch.
What is special about the polyorthoester claims (Claims 17–20, 21, 27–36)?
The patent tightens around polyorthoester chemistry through extensive variable-driven definitions.
Polyorthoester formula coverage (Claims 19–20)
Polyorthoester-based delivery composition with viscosity modifiers (Claims 21–28)
Claim 21 is the most product-like and commercially relevant subcombination inside the polyorthoester lane. It requires the delivery system comprises:
- polyorthoester
- polar aprotic solvent
- triglyceride viscosity reducing agent with:
- three fatty acid groups
- each fatty acid has 1–7 carbon atoms
- plus the drug ratio: amide local anesthetic : meloxicam is 10:1 to 50:1
Dependent narrowing
- Claim 22: triglyceride viscosity reducing agent is triacetin or tributyrin
- Claim 23: polar aprotic solvent is DMSO, NMP, or dimethylacetamide
- Claim 24: solubility of both actives in triglyceride and/or polar aprotic solvent
- Claims 25–26:
- anesthetic (amide local anesthetic) 0.01 to 7.5 wt%
- meloxicam 0.005 to 0.25 wt%
Concrete composition ranges
- Claim 27: delivery system comprises:
- 40–75 wt% polyorthoester
- 5–12 wt% DMSO
- 20–40 wt% triacetin
- 1–5 wt% bupivacaine or ropivacaine
- 0.005–1 wt% meloxicam
- Claim 28:
- further includes 0.01–0.30 wt% maleic acid
This set is a direct infringement magnet: it describes a specific formulation “recipe” around polyorthoester plus triacetin plus DMSO, with tight viscosity and solubility framing.
Further polyorthoester molecular weight and rheology constraints (Claims 36–38, 39–40)
- Claim 36: polyorthoester has Mw 2,500 to 10,000 Da
- Claim 37: delivery system viscosity < 10,000 mPa-s at 37°C
- Claim 38: anesthetic and meloxicam are solubilized in a single phase
- Claim 39: composition is extended-release
- Claim 40: anesthetic released over 1 to 5 days
How are the pharmacology and release outcomes framed (Claims 41–54)?
The patent includes multiple use claims that are tied to administration routes and measurable time dynamics.
Indication/use scope
- Claim 41: method for producing analgesia or pain relief
- Claim 42: method for managing pain
- Claim 43: method for prophylactic treatment of pain
Route and target
- Claim 44: intramuscular, subcutaneous, perineural, or to a wound
- Claim 46: administer to a surgical wound
- Claim 49-50: nerve block / peripheral nerve block
Pain type
- Claim 45: acute or chronic pain
- Claim 47: postsurgical pain
- Claim 48: pain relief 3 to 5 days post-administration
Performance profile (Claims 51–54)
Claim 51 requires, in an in vivo postsurgical pain model:
- initial decrease in pain relief between 1 hour and 24 hours
- followed by increased pain relief between days 1–3
- the initial decrease is relative to pain relief immediately post-dose
Claim 52
- days 2 to 5 pain relief is at least 50% of the pain relief at 1–5 hours
Claim 53
- provides measurable plasma concentrations of both actives for up to 5 days
Claim 54
- about 80% by weight or more of both anesthetic and meloxicam are released over up to 3 days in vitro at 37°C
This gives the patent a measurable, defense-oriented release phenotype.
What are the practical infringement and design-around pressure points?
Primary “hard” elements
- Drug pair and ratio: amide local anesthetic + meloxicam with 10:1 to 50:1 ratio in the composition, and no other active agents (Claim 1).
- Identity of anesthetic: bupivacaine and/or ropivacaine are singled out (Claims 2–3).
- Sustained release: required (Claim 5) and reinforced by specific release windows (Claim 40).
- Delivery system variants: the patent spans multiple systems, but the polyorthoester + triacetin + DMSO recipe is the most specific.
Where competitors can seek safer harbor
- Avoiding the ratio window or adding additional active agents may remove literal coverage for Claim 1. But enforcement depends on claim construction and whether doctrine of equivalents is argued.
- Using sustained-release but not matching the delivery-system-dependent dependent-claim features may dodge narrower dependent claims, while still potentially implicating Claim 1 if the product includes the ratio and no other actives.
- The polyorthoester-specific dependent claims provide high specificity, so designing around the exact polyorthoester family, molecular weight, viscosity profile, or excipient set could avoid those narrower lanes.
US patent landscape: how this claim set positions against typical competitors
What this patent most resembles in the landscape
This patent sits at the intersection of:
- local anesthetic depots (bupivacaine/ropivacaine sustained-release delivery)
- NSAID analgesia (meloxicam)
- combination analgesic regimens intended for post-surgical pain duration of days
- polymer depot formulations, with an especially detailed polyorthoester approach
Landscape mechanics that matter for enforcement
Because the patent is built on a combination composition with a ratio limitation plus wide delivery system coverage, enforcement typically targets:
- injectable depot products that include both actives in one formulation
- formulations aimed at postsurgical analgesia where release kinetics match the claim phenotype
- products using polyorthoester and matching excipient/rheology specifications (for narrower dependent claims)
In practical terms, the strongest litigation leverage comes from matching the detailed recipe of Claim 27 and performance structure of Claims 51–54.
Core competitor categories likely mapped to this perimeter
- Single-injection depot anesthetic products (if they add meloxicam as a co-active within the same composition)
- Topical or systemic meloxicam combinations that use another anesthetic but not the claimed ratio and no additional actives
- Drug-device or polymer depot hybrids that include bupivacaine/ropivacaine plus meloxicam without matching polyorthoester + triacetin + DMSO delivery parameters
(Those categories reflect how the claims are drafted, not a provable list of specific granted US patents without retrieving the full patent file and cited prior art.)
Claim-by-claim scope map (actionable for FTO)
Composition claims
| Claim |
What it adds |
Coverage impact |
| 1 |
Composition: delivery system + amide local anesthetic + meloxicam; ratio 10:1 to 50:1; no other actives |
Broadest independent perimeter |
| 2 |
anesthetic is bupivacaine |
narrows within Claim 1 |
| 3 |
anesthetic is ropivacaine |
narrows within Claim 1 |
| 4 |
loading: anesthetic 0.1–8.0 wt%; meloxicam 0.005–1% |
tightens drug-loading window |
| 5 |
sustained-release delivery |
locks to extended release |
| 6 |
aqueous based |
medium limitation |
| 7 |
delivery system types allowed |
broad platform menu |
| 8 |
liposome subtype |
narrowed liposome embodiments |
| 9 |
entrapped location |
narrows liposome entrapment |
| 10 |
microsphere polymeric and biodegradable |
microsphere limitation |
| 11 |
entrapped in microsphere |
both actives entrapped |
| 12 |
osmotic pump reservoir |
device-specific lane |
| 13 |
non-polymeric: sucrose acetate isobutyrate |
non-polymeric specific lane |
| 14 |
semi-solid polymer formulation |
polymer depot lane |
| 15 |
biodegradable polymer |
further narrowing |
| 16 |
depot/implant in situ |
depot mechanism |
| 17 |
polymer family including polyorthoesters |
sets candidate polymers |
| 18 |
polyorthoester selected |
pivots into polyorthoester-specific scope |
| 19–20 |
polyorthoester formulas/parameters |
chemical structure constraints |
| 21 |
delivery system includes polyorthoester + polar aprotic solvent + triglyceride viscosity reducing agent + ratio |
product recipe lane |
| 22 |
viscosity agent = triacetin or tributyrin |
narrows excipient |
| 23 |
polar aprotic solvent set |
narrows excipient |
| 24 |
solubility in those excipients |
process/solubility constraint |
| 25–26 |
anesthetic and meloxicam wt% ranges |
narrows loadings |
| 27 |
full composition wt% ranges with DMSO and triacetin |
main formulation claim |
| 28 |
maleic acid optional range |
additional excipient |
| 29–35 |
further polyorthoester structure constraints |
tighter polymer spec |
| 36 |
polyorthoester Mw |
molecular weight constraint |
| 37 |
viscosity <10,000 mPa-s at 37°C |
rheology constraint |
| 38 |
single-phase solubilization |
phase structure constraint |
| 39 |
extended-release |
redundant to Claim 5 but reinforces |
| 40 |
release over 1–5 days |
release kinetic window |
Method claims
| Claim |
What it requires |
Coverage impact |
| 41–43 |
analgesia/pain relief, management, prophylaxis |
broad use language |
| 44 |
routes including perineural and wound |
administration options |
| 45–47 |
acute/chronic and postsurgical |
sets pain context |
| 48 |
pain relief 3–5 days |
outcome timeline |
| 49–50 |
nerve block / peripheral nerve block |
procedural sub-scope |
| 51–54 |
in vivo pain relief time profile, plasma C measurable to 5 days, release extent |
strongest measurable phenotype |
Key Takeaways
- US 11,083,730 claims a two-active-only analgesic composition pairing an amide local anesthetic with meloxicam, constrained by a 10:1 to 50:1 ratio and explicit exclusion of additional active agents (Claim 1).
- The patent covers multiple sustained-release delivery platforms (liposomes, microspheres, osmotic pumps, polymer depots, non-polymeric sustained-release), but the most enforcement-ready lane is the polyorthoester + DMSO + triacetin formulation set with specific wt% ranges (Claim 27) and viscosity/Mw constraints (Claims 36–37).
- The use claims incorporate measurable pharmacodynamic/release behaviors: a post-dose pain relief dip followed by increased relief days 1–3, sustained relief days 2–5 at ≥50% of early relief, measurable plasma exposure to 5 days, and ≥80% release by up to 3 days in vitro (Claims 51–54).
- For FTO and design-around planning, the dominant levers are: ratio compliance, presence of any additional actives, delivery system classification, and matching or avoiding the detailed polyorthoester excipient and rheology recipe.
FAQs
1) What is the single most important claim limitation to avoid for literal non-infringement?
The composition must avoid having an amide local anesthetic plus meloxicam at 10:1 to 50:1 while containing no additional active agents (Claim 1).
2) Does the patent require bupivacaine or ropivacaine in the independent claim?
Claim 1 generically requires an amide local anesthetic; bupivacaine and ropivacaine are specified in dependent claims (Claims 2–3).
3) Which claims are most formulation-specific for enforcing infringement?
Claims 21–28 and 27 are the tightest: polyorthoester + polar aprotic solvent + triacetin/tributyrin with defined wt% ranges and optional maleic acid.
4) Are release and pharmacokinetic outcomes part of the claim set?
Yes. Claims 51–54 set time-profile pain relief expectations, plasma detectability up to 5 days, and ≥80% release by up to 3 days in vitro at 37°C.
5) How do the delivery system claims affect design-around strategy?
Because Claim 1 is broad on “delivery system” but dependent claims specify many modalities, a design-around typically focuses on dodging the combination ratio and also selecting a delivery system and excipient package that avoids the most specific dependent claim lanes.
References
[1] United States Patent 11,083,730 (claims provided in user prompt).
